JP2019054788A - Composition for preventing and suppressing deterioration of estimated glomerular filtration rate and renal function - Google Patents

Abstract

An object of the present invention is to provide a composition for suppressing a decrease in estimated glomerular filtration rate containing amperopsin as an active ingredient and a composition for suppressing a decrease in renal function.
A composition for preventing or suppressing a decrease in estimated glomerular filtration rate, which comprises amperopsin as an active ingredient.
[Selection] Figure 1

Description

  The present invention relates to an estimated glomerular filtration rate and a composition for preventing / suppressing a decrease in renal function, which contains amperopsin as an active ingredient.

  The kidney is an important organ that plays a role in excreting biological waste products. Histologically, there are about 1 to 1.2 million nephrons in the right and left kidneys, and nephrons are composed of renal bodies and tubules (renal tubules). Furthermore, the renal body is composed of glomeruli and Bowman's sac, and the tubule is composed of proximal tubule, Henle loop and distal tubule. Each of these tissues has an important function. Among them, the glomerulus plays an important role in discharging waste products. One human kidney weighs only about 150 g, but the amount of blood inflow / outflow per organ weight is about five times that of the heart and about eight times that of the brain. (The amount of blood flowing to the kidney is about 1 to 1.2 L per minute). The kidneys have various functions, but the most important function is to maintain the "quality" and "quantity" of the body fluids that have spread throughout the body, including the cells, by regulating blood components and maintaining the balance of the body. This function is essential for the maintenance of homeostasis (homeostasis).

A decrease in glomerular filtration rate is directly linked to a decrease in kidney function. Decreased renal function carries the risk of developing renal failure, and chronic renal failure leads to a decrease in glomerular filtration rate (GFR). The amount of glomerular filtration is used as one of the important indicators of kidney function, and is measured by clearance tests such as creatinine clearance and inulin clearance. Urea nitrogen (BUN) also reflects kidney function, but creatinine clearance is a better indicator of kidney function in that it is not affected by external factors. Inulin clearance has long been the standard method for measuring glomerular filtration rate. Sex creatinine clearance is commonly used. Therefore, a decrease in creatinine clearance indicates a decrease in kidney function and is an indicator of kidney dysfunction.
Glomerular filtration rate is the amount of plasma filtered by all glomeruli of the kidney per unit time, and the unit is mL / min or L / day. Inulin clearance is used to accurately measure glomerular filtration rate, but creatinine clearance or eGFR (estimated GFR; estimated glomerular filtration rate) is often used in medical practice. The unit is mL / min / 1.73 m ² . Since it is impossible to filter the glomerulus in renal failure, the degree of progression can be known by measuring the estimated glomerular filtration rate. Therefore, it becomes a standard to introduce artificial dialysis in chronic renal failure.
Normally, the amount of glomerular filtration decreases only from the normal value and does not increase, but it is known that the glomerular filtration rate temporarily increases in the early stage of diabetic nephropathy.

  In view of the above, for the purpose of improving glomerular filtration rate, therapeutic agents for renal failure and evaluation of the effect of treatment have been performed (Patent Document 1, Patent Document 2, Patent Document 3).

  Against such a background, the present inventors are searching for substances that suppress a decrease in the estimated glomerular filtration rate of natural products and natural extracts. They discovered that Fuji tea, a traditional food in China and Southeast Asia, has an effect of suppressing the decrease in estimated glomerular filtration rate. It is known that Fuji tea has various medicinal effects. The action is diverse, such as the effect of treating liver diseases such as acute hepatitis (Patent Document 4), the antibacterial effect (Patent Document 5), and the anti-pigmentation effect (Patent Document 6). However, it has never been known until now that Fuji tea has the effect of suppressing the decrease in the estimated amount of glomerular filtration and improving and treating renal failure.

International Publication No. 2004/098611 JP 2007-327921 A JP 2012-236820 A Japanese Patent Laid-Open No. 2003-026584 Japanese Patent Application Laid-Open No. 2002-1559566 JP 2002-066511

The present inventors have conducted research based on the background art as described above, and Fuji tea extract has a strong preventive / suppressive action on the estimated glomerular filtration rate, and has a preventive / suppressive action on renal function decline. I have found it. As a result of further research, the inventors have found that the substance exhibiting the effect of suppressing the decrease in estimated glomerular filtration rate is amperopsin, which is a kind of flavonoid contained in Fuji tea, and has made the present invention.
That is, the subject of this invention is providing the composition for the fall prevention / suppression of the estimated glomerular filtration rate which uses amperopsin as an active ingredient, and the composition for a renal function fall prevention / suppression. Furthermore, it is providing the food / beverage products for prevention / suppression of the fall of renal function and the food / beverage products for fall prevention / suppression of the estimated glomerular filtration rate.

The main configuration of the present invention is as follows.
(1) A composition for suppressing a decrease in estimated glomerular filtration rate or for preventing a decrease in estimated glomerular filtration rate, comprising amperopsin as an active ingredient.
(2) A composition for suppressing a decrease in estimated glomerular filtration rate or for preventing a decrease in estimated glomerular filtration rate, comprising 10% by mass or more of amperopsin.
(3) A composition for suppressing a decrease in the estimated glomerular filtration rate or for preventing a decrease in the estimated glomerular filtration rate, comprising a Fuji tea extract.
(4) The composition according to (3), which contains amperopsin in an amount of 10% by mass or more.
(5) A composition for preventing / suppressing renal function deterioration containing 10% by mass or more of amperopsin.

  The present invention provides a composition for preventing or suppressing a decrease in the estimated amount of glomerular filtration. In addition, a composition for preventing / suppressing renal function deterioration is provided.

It is a graph which shows the time-dependent change of the estimated glomerular filtration rate by the double-blind comparative test between the placebo control parallel groups which evaluates the influence of amperopsin administration with respect to a human. It is a graph which shows the analysis result of urinary creatinine in an animal test. It is a graph which compares the amount of urinary amperopsine of a salt load mouse | mouth and a salt load amperopsin administration mouse | mouth.

The present invention is an invention relating to a composition for preventing and suppressing the decrease in estimated glomerular filtration rate, which contains amperopsin as an active ingredient.
Fuji tea is a plant belonging to the genus Ganoderma genus, and its Chinese name is called dentition gabion. The scientific name is Ampelopsis grossedentata. It is mainly distributed in provinces and autonomous regions of China such as Guangxi, Guangdong, Yunnan, Guizhou, Hunan, Hubei, Jiangxi, Fujian. Chinese and Chinese provinces such as Guangxi, Hunan and other autonomous and barbaric people regularly use beverages made from these stems and leaves and are used for colds and sore throats. Amperopsin has been identified as the active body of the therapeutic and antibacterial effects of liver diseases exhibited by Fujicha.

  Ampelopsin is represented by the following formula.

  Ampelopsins include, for example, wisteria tea (Ampelopsis grossedenta), Ampelopsis megalophylla, Ampelopsis cantoniensis, black peas (Hovenia dulcis), Heniais t. It can be isolated and purified from an extract of a plant selected from (Erythrophureum africanum) and wig (Cerciphyllum japonicum). Among these, Fuji tea is preferable.

Specifically, amperopsin can be obtained as follows from Fuji tea (Amelopsis grossedenta), a plant belonging to the genus Ampelopsis.
That is, the extract obtained by extracting the dried leaves and leaves of wisteria tea with water-containing ethanol was concentrated, and subjected to column chromatography using, for example, a porous resin (DIAION (registered trademark) HP-20), and with 80% by volume water-containing methanol. Ampelopsin is obtained in the eluted fraction. This can be further purified by silica gel column chromatography or recrystallization. Purified amperopsin is also sold as a reagent and can be used.

The composition of the present invention can be used as long as it contains 10% by mass or more of the above-mentioned amperopsin. In order to obtain such a composition from Fuji tea, the following operation is performed.
Using dried wisteria tea leaf or stalk pulverized material or powder as an extraction raw material, it is poured into water, a hydrophilic organic solvent or a mixed solvent thereof, and extracted using an arbitrary apparatus at a temperature between room temperature and the boiling point of the solvent. Can be obtained.

Examples of organic solvents used for extraction include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene glycol, propylene glycol, Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as propylene glycol and glycerin.
Moreover, a mixed solvent of these hydrophilic organic solvents and water can be used. In the case of using a mixed solvent of water and a hydrophilic organic solvent, 30 to 90 parts by mass with respect to 10 parts by mass of water in the case of a lower alcohol, and 10 parts by mass of water in the case of a lower aliphatic ketone. In contrast, 10 to 40 parts by mass, and in the case of polyhydric alcohol, 10 to 90 parts by mass are preferably added to 10 parts by mass of water.

  Into a treatment tank filled with the extraction solvent, dried and pulverized product of Fuji tea is added, and the mixture is left to stand for 30 minutes to 2 hours with occasional stirring. , And the extractant is distilled off from the extract and dried to obtain an extract. The amount of the extraction solvent is preferably 5 to 15 times the mass of the extraction raw material (mass ratio), and the extraction conditions are usually 50 to 95 ° C. for about 1 to 4 hours when water is used as the extraction solvent. It is. Moreover, when using the mixed solvent of water and ethanol as an extracting solvent, it is about 30 minutes-about 4 hours at 40-80 degreeC normally.

When the extraction solvent is distilled off from the obtained extract, a paste-like concentrate is obtained. When further dried, a solid extract is obtained. In the present invention, as long as the content of amperopsin is 10% by mass or more, preferably 20% by mass or more, the extract or the concentrated solution thereof may be used. These may be used after being purified by a method such as activated carbon treatment, adsorption resin treatment, ion exchange resin, liquid-liquid countercurrent distribution or the like.
Therefore, an extract obtained by extracting from the above-mentioned wisteria tea and increasing the concentration of amperopsin can also be used as the composition of the present invention.

The content of amperopsin in the composition can be analyzed by a known analysis method such as HPLC. The outline of the quantification method is as follows.
-Preparation of sample solution About 20 mg of a sample (extract) is precisely weighed, distilled water is added and sonicated to dissolve, and the volume is made exactly 50 mL. 2 mL of this solution is accurately diluted to 50 mL to obtain a sample solution.
・ Preparation of standard solution and preparation of calibration curve
2.00 mg of a standard product (manufactured by Dihydromyricin SIGMA-ALDRICH) is precisely weighed, and 100% acetonitrile is added in an appropriate amount to be sonicated to dissolve, and further acetonitrile is added to make exactly 25 mL. Prepare. This standard stock solution is diluted exactly 5 times with distilled water to prepare a 16 μg / mL amperopsin standard solution. The injection amount to HPLC is 10, 20, and 40 μL, and a calibration curve is created based on the peak of amperopsin.
-HPLC measurement conditions Set the conditions in Table 1 below.

The composition for preventing and suppressing the decrease in the estimated glomerular filtration rate of the present invention is formulated as it is or by adding various excipients. Examples of the preparation include granules, tablets, and capsules.
Moreover, the composition can be used as a food or drink as it is, or a formulated product can be used as a medicine or food or drink.
In the preparation, excipients and other active ingredients can be used as long as the purpose of the composition of the present invention is not impaired. Specifically, cyclodextrin, hemicellulose, lignin, guar gum, konjac mannan, isagor, alginic acid, agar, carrageenan, chitin, carboxymethylcellulose, polydextrose and other dietary fibers and thickeners, edible oil, calcium, iron, Minerals such as sodium, zinc, copper, potassium, phosphorus, magnesium, iodine, manganese, selenium; fat-soluble or water-soluble such as vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, niacin, folic acid, pantothenic acid Emulsifiers and dispersants such as vitamins, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, phospholipid, gum arabic, xanthan gum, tragacanth gum, locust bean gum, Quantitatives, preservatives / antioxidants, flavor modifiers and fragrances, sodium chloride, sodium glutamate, glycine, succinic acid, sodium lactate and other flavoring agents, citric acid, sodium citrate, acetic acid, adipic acid, fumaric acid, Acidulants such as malic acid, low calorie sweeteners such as maltitol and aspartame, and coloring agents.
In addition, the composition for preventing or suppressing the decrease in the estimated glomerular filtration rate of the present invention is prepared so as to contain amperopsin in an amount of 10 to 2500 mg, preferably 50 to 300 mg, particularly preferably 100 to 200 mg.

<Example of production of Fuji tea extract>
The production examples of the composition of the present invention and test examples using this composition are shown below to further explain the present invention.
<Production example>
An extract was obtained with 70% ethanol in an amount 10 times the weight of dry wisteria tea. Thereafter, the extract was concentrated and filtered while removing impurities using activated carbon. An appropriate amount of γ-cyclodextrin was added to the concentrate, and the composition of the present invention was produced by spray drying. This was pulverized to obtain a composition for preventing and suppressing a decrease in estimated glomerular filtration rate.

<Human test>
The effect on human estimated glomerular filtration rate was tested.
1. Test Method (1) Test Product (hereinafter “Test Food”)
As the test food, 150 mg of amperopsin-containing capsule (Fujicha extract powder 500 mg) and 500 mg of starch-containing capsule as placebo were used.
(2) Test subjects The volunteers selected at random were selected to meet the following selection criteria.
1) Selection criteria (1) Persons whose blood pressure (systole) in the screening test is 130 mmHg or more and less than 160 mmHg (2) Persons who can go to an examination site whose age at the time of obtaining consent is between 20 and 80 years old (3) Person with BMI of 18.5 kg / m ² or more and less than 30.0 kg / m ² (4) Person who has obtained document consent

2) Exclusion criteria (1) Severe gastrointestinal disease, liver disease, kidney disease, cardiovascular disease, blood disease, endocrine system disease, or malignant neoplasm Those who have been diagnosed with left ventricular hypertrophy (3) Those who have secondary hypertension (4) Those who may cause allergies to vines (5) Currently taking antihypertensive drugs or receiving antihypertensive treatment by a doctor (6) Those who are scheduled to receive medical treatment or medication during the study period (7) Those who are scheduled to take foods for specified health use, functional labeling foods and other supplements during the study period ( 8) Persons whose dietary habits (number of meals, meal content, alcohol intake) may change during the test period (9) Persons who may change their lifestyle during the test period (night work, long-term work) Travel, transfer, etc.)
(10) Currently smoking or who has smoked within the past year (11) Estimated daily salt intake by screening urine test is less than 8.0 g for men and less than 7.0 g for women (12) Pregnant or pregnant women or breastfeeding women (13) Those who plan to participate in other clinical trials during the study period (14) Other doctors judged inappropriate Person

(3) Evaluation item 1) Main evaluation item Estimated glomerular filtration rate Estimated glomerular filtration rate (eGFR) is obtained by the following formula.
Male: eGFR (ml / min / 1.73 m ² ) = 194 x Cr-1.094 x age -0.287
Female: eGFR (ml / min / 1.73 m ² ) = 194 x Cr-1.094 x age -0.287 x 0.739

2) Safety evaluation items Adverse events, laboratory values

(4) Administration study 1) Study design Double-blind comparative study between placebo-controlled parallel groups

2) Test period (14 weeks)
The initial observation period is before taking Fujicha extract powder. Thereafter, the subjects are randomly divided into two groups and ingested with 500 mg of Fujicha extract powder or placebo for 12 weeks.
There are 5 visits to the test facility: screening test, start date of intake, 4 weeks after intake, 8 weeks after intake, and 12 weeks after intake.

Study period The initial observation period and intake period will be 14 weeks in total.

3) Ingestion method After confirming that the selection and exclusion criteria are not violated, ingestion of the test food (Fujicha extract powder) or placebo is started once a day after breakfast.

Ingestion period 12 weeks Ingestion method Oral intake of 3 tablets once a day after breakfast Observation period 1 week before and after the intake period

4) Concomitant drugs / combination therapy Use of concomitant drugs and combination therapy are prohibited in principle. However, treatment can be started as necessary at the discretion of the doctor. Investigate drug use, dosage, duration, etc. regarding the use of drugs.

5) Survey items (1) Background survey The screening test will investigate age, gender, current medical history, past medical history, and life history (smoking, alcohol consumption, medication use, health food use).

(2) Blood test General blood test (white blood cell count, red blood cell count, hemoglobin, hematocrit, MCV, MCH, MCHC, platelet count), general biochemical test (TG, TC, HDL-C, LDL-C, blood glucose, HbA1c (NGSP) ), Γ-GTP, AST, ALT, total bilirubin, total protein, albumin, A / G ratio, ALP, LDH, CPK, creatinine, uric acid, urea nitrogen, Na, K, Cl, LAP), chymase, renin, aldosterone Measure.
The blood test will be performed on a fasting basis, twice a screening test and a test 12 weeks after ingestion.
For urinalysis, spot urine is used to measure urinary Na and urinary Cr. Estimated daily salt intake is calculated and examined monthly to observe changes in salt intake over time. In addition, urinary albumin is measured only for screening tests to confirm safety.

(3) Chest photography / load electrocardiogram, ABI, PWV
Conduct screening to confirm safety. The loading method in the ECG measurement is going up and down stairs.

(4) Meal survey The meal content on the day before the examination will be investigated on the visit day.

(5) Diary Investigate alcohol consumption, changes in eating habits, changes in physical condition, and intake of test foods.

6) Criteria for withdrawal ・ If the subject asks for withdrawal ・ If the investigator determines that it is not desirable to continue the study due to an adverse event ・ Other cases where the investigator determines that cancellation is necessary

7) Adverse events (1) Severity of adverse events-Mild: Adverse events that do not interfere with daily activities-Moderate: Adverse events that interfere with daily activities-Severe: Inability to conduct daily activities Adverse event

(2) Serious adverse events ・ Things that lead to death ・ Things that are life-threatening Note: This refers to the case where the patient is at risk of death at the time of the occurrence of the event. It does not mean that it may be.
・ Things requiring hospitalization or extension of length of stay for treatment ・ Permanent or significant disability ・ Dysfunction ・ Congenital anomalies ・ Other medically important events or reaction

(3) Relevance to the test food ・ None: There is no reasonable possibility with the test food ・ Yes: There is at least a reasonable possibility with the test food, and the causal relationship cannot be denied・ Unknown: When the causal relationship with the test food cannot be determined due to lack of information

(4) Outcomes The outcome of adverse events is determined according to the following 6 levels.
・ Recovery ・ Lightness ・ Not recovered ・ Recovered but with sequelae ・ Death ・ Unknown

(5) Reporting when a serious adverse event occurs After a serious adverse event has occurred and the investigator knows the adverse event, the report is promptly reported to the head of the study site. And report on serious adverse events and submit it to the head of the study site.

8) Statistical analysis Perform a two-way analysis of variance.

2. Number of test cases The total number of cases that can be analyzed is 12 in 6 groups in each group.

3. Test results The test results are shown in FIG.
In the test food intake group (Fujicha), the estimated glomerular filtration rate did not decrease even after 12 weeks of administration. On the other hand, the placebo group showed a decrease in estimated glomerular filtration rate. As a result of comparison between the test food intake group and the placebo group, a significant difference was observed between the two groups after 12 weeks.
As a result of comparison between the Fujicha extract intake group and the placebo intake group containing amperopsin, it was confirmed that the estimated glomerular filtration rate was maintained in the Fujicha intake group and the placebo group was decreased. Adverse events were not observed and no subjects discontinued.
As a result of the above-mentioned placebo-controlled parallel-blind double-blind comparative test, amperopsin prevents and suppresses the decrease in glomerular filtration rate over time, and thus can be expected to prevent and suppress the decrease in renal function.

<Animal test>
In order to confirm the effect of amperopsin on renal function by an animal test using mice, a test example in which changes in the amount of creatinine by administration of sodium chloride were confirmed is shown below.
1. Test method (1) Test product: Fuji tea extract (hereinafter referred to as “Fuji tea”) (containing 300 mg of amperopsin per 1 g)
(2) Animal species: mouse strain: C57BL / 6J
Microbiological grade: SPF
Gender: Male Age at acquisition: 6 weeks Age at administration: 7 weeks Age of use: 18 Animals Source: Nippon SLC

(3) Quarantine and acclimatization Quarantine and acclimatization period: 6 days including the date of acquisition Observation and measurement: At the time of acquisition, the health condition of the animal is confirmed macroscopically. The animals were quarantined and acclimatized for 6 days under the same breeding conditions and breeding environment. During the quarantine / acclimation period, body weight was measured using an electronic balance (UW4200S, Shimadzu Corporation) on the daily general condition observation and the date of acquisition and the end of quarantine. No abnormalities were observed in the general condition during the quarantine / acclimation period, and weight gain was good.

(4) Identification method Individual identification: An individual identification number was written on the ridge with a felt pen at the time of acquisition. After grouping, identification was made using a correspondence table between temporary numbers and real numbers.

(5) Feed type: Solid feed MF
Supply source: Oriental Yeast Co., Ltd. Feeding method: Feed was placed in a stainless steel feeder and allowed to freely ingest.

(6) Drinking water 1) During the quarantine acclimation period and before the start of administration Type: Tap water Water supply method: Tap water was placed in a transparent polycarbonate water bottle and allowed to freely ingest through a metal nozzle.
2) After administration start Type: 2% saline Preparation method: Weigh 160 g of sodium chloride with an electronic balance and dissolve in distilled water (fully automated distilled water production equipment Aquarius, GSH-500, Advantech Toyo Co., Ltd.) 8000 mL It was.
Water supply method: Put in a transparent polycarbonate water bottle and let it inhale freely through a metal nozzle.

(7) Test group configuration Three groups shown in Table 2 below were set using 6 animals per group.

(8) Extraction of test animals and grouping method Randomized stratified allocation from animals with normal weight gain during the quarantine / acclimation period on the day before the start of administration and no abnormalities in the general condition (layer: body weight, bilayer) : Systolic blood pressure).

(9) Test days The test days were defined as “Day 0” as the test product administration start date.

(10) Body weight measurement Measurement frequency: Day-1, 7, 14, 21, and 28
Number of test animals: 18 Measurement method: Measured using an electronic balance (UW4200S, Shimadzu Corporation).

(11) Administration method of test product Administration route: Oral administration Number of animals administered: 18 animals Dose: 600 mg / kg
Dosing volume: 10 mL / kg (Dose was calculated based on the latest body weight)
Administration method: Forced administration using a disposable syringe made of polypropylene and a gastric sonde for mice.
Number of administrations: 1 day / day for 28 days (Day 0 to Day 27).

(12) Measurement of water intake Measurement frequency: Measured at a rate of once every 3 days after the start date of administration.
Number of implemented animals: 18 Measurement method: Measured using an electronic balance (UW4200S, Shimadzu Corporation).

(13) Urine collection Frequency: Before start of administration and Day 26 to 27
Number of animals: 18 Collection / treatment method: Urine was collected for 24 hours using a metabolic cage. Urine was collected and weighed using an electronic balance (AG204DR, METTLER TOLEDO Co., Ltd.), and then stored frozen in a cryogenic bath.

(14) Measurement of urinary creatinine Urinary creatinine was measured by Oriental Yeast Co., Ltd. using L-type Wako CRE / M manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.

(15) Statistical treatment The measured values are expressed as mean ± standard error (mean ± SE) for each group. A significant difference test was performed between the tap water load group, the control 2.2% saline load group, and the Fuji tea + 2% saline load group.

2. Test results (1) Body weight All animals in the test group showed a steady increase in body weight.

(2) Water intake test group control 1. When the tap water load group and the control 2.2% saline load group are compared, the control 2.2% saline load group has a significantly high water consumption from Day 4 to the last measurement day (Day 25) (p <0.01). showed that. Control 1. Comparing the tap water load group with the Fuji tea + 2% saline load group, the Fuji tea + 2% saline load group showed a high water consumption from Day 4 to the last measurement day (Day 25). When the control 2.2% saline-loaded group and the Fuji tea + 2% saline-loaded group were compared, no difference was observed.

(3) Urinary creatinine level The measurement results of the urinary creatinine level, which is one of the renal function markers, are shown separately in FIGS. 2 and 3 for statistical processing.
In administration Day 27, control 1. When the tap water load group and the control 2.2% saline load group were compared, the urinary creatinine amount showed a high value <0.05 in the control 2.2% saline load group (FIG. 2). Control 1. When the tap water load group was compared with the 2% saline + Fuji tea group, no difference was observed (FIG. 2).
When the control 2.2% saline group and the 2% saline + Fuji tea group were compared, the 2% saline + Fuji tea group showed a low value (P <0.1) (FIG. 3).
From this result, it can be judged that Fujicha suppressed renal dysfunction induced by the drinking load of 2% saline, and that the urinary creatinine level decreased. That is, the composition containing ampelopsin has an action to prevent / suppress renal function decline.

Claims (5)

  A composition for suppressing a decrease in estimated glomerular filtration rate or for preventing a decrease in estimated glomerular filtration rate, comprising amperopsin as an active ingredient.   A composition for suppressing a decrease in estimated glomerular filtration rate or for preventing a decrease in estimated glomerular filtration rate, comprising 10% by mass or more of amperopsin.   A composition for suppressing a decrease in estimated glomerular filtration rate or for preventing a decrease in estimated glomerular filtration rate, comprising a Fuji tea extract.   The composition according to claim 3, which contains 10% by mass or more of amperopsin.   A composition for preventing / suppressing a decrease in renal function, comprising 10% by mass or more of amperopsin.